Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.

International journal of cancer - 1 Sept 2007

Soh Junichi, Toyooka Shinichi, Ichihara Shuji, Fujiwara Yoshiro, Hotta Katsuyuki, Suehisa Hiroshi, Kobayashi Naruyuki, Ichimura Kouichi, Aoe Keisuke, Aoe Motoi, Kiura Katsuyuki, Date Hiroshi

Abstract excerpt

We previously examined the relationship between epidermal growth factor receptor (EGFR) status and clinical outcomes of nonsmall-cell lung cancer (NSCLC) patients treated with gefitinib. In our study, we additionally examined HER2 status and investigate the impact of genetic status as predictors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Genes, erbB-2

Share to In Situ Hybridization, Fluorescence

Share to Quinazolines

Source

Identifiers

PMID: 17487844
DOI: 10.1002/ijc.22818

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17487844-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.PMID 17487844Read ↗

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.Semantic proximity Read ↗

HER2 mutations in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Increased<i>HER2</i>Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.Semantic proximity Read ↗

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.Semantic proximity Read ↗

Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.Semantic proximity Read ↗

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.Semantic proximity Read ↗

EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.